Kazia begins phase II study into paxalisib + a keto diet to treat brain cancerKazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer) Posted on March 23rd, 2022 . Updated on April 11th, 2022 by Cherie HartleyKazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)